Published in J Clin Invest on January 11, 2016
Long Noncoding RNAs in Cancer Pathways. Cancer Cell (2016) 1.63
Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus (2016) 0.85
CCAT1: an oncogenic long noncoding RNA in human cancers. J Cancer Res Clin Oncol (2016) 0.79
Cancer subtypes classification using long non-coding RNA. Oncotarget (2016) 0.78
Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. Cancers (Basel) (2017) 0.78
Prognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysis. PLoS One (2017) 0.76
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut (2016) 0.76
Unusual semi-extractability as a hallmark of nuclear body-associated architectural noncoding RNAs. EMBO J (2017) 0.75
Validation of Synthetic CRISPR Reagents as a Tool for Arrayed Functional Genomic Screening. PLoS One (2016) 0.75
The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Clin Cancer Res (2016) 0.75
Long non-coding RNAs: a rising biotarget in colorectal cancer. Oncotarget (2017) 0.75
A novel RNA sequencing data analysis method for cell line authentication. PLoS One (2017) 0.75
Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun (2017) 0.75
To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. Int J Mol Sci (2017) 0.75
CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery. Trends Cancer (2016) 0.75
Long noncoding RNA lnc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment. Cell Cycle (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Cancer genome landscapes. Science (2013) 25.33
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Widespread transcription at neuronal activity-regulated enhancers. Nature (2010) 16.52
RNA-programmed genome editing in human cells. Elife (2013) 14.82
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell (2013) 9.55
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell (2005) 8.95
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell (2005) 8.92
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Lessons from the cancer genome. Cell (2013) 8.12
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature (2011) 6.10
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Myc deletion rescues Apc deficiency in the small intestine. Nature (2007) 5.42
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg (2009) 5.38
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol (2013) 4.72
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell (2014) 3.13
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 2.91
Targeting epigenetic readers in cancer. N Engl J Med (2012) 2.86
CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res (2008) 2.65
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell (2014) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8 methyltransferase, Prmt2. Dev Cell (2010) 2.44
The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem (2008) 2.40
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol (2014) 2.17
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem (2013) 2.09
Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84
Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res (2014) 1.83
An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev (2014) 1.73
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics (2009) 1.68
Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis (2015) 1.67
Colon cancer: it's CIN or CIMP. Clin Cancer Res (2008) 1.41
The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. Adv Drug Deliv Rev (2010) 1.36
CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res (2012) 1.35
Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J Biol Chem (2012) 1.30
pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27
Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle (2012) 1.26
BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol (2014) 1.25
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn (2007) 1.17
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion. Cancer Res (2011) 1.16
The epigenetics of colorectal cancer. Ann N Y Acad Sci (2000) 1.16
Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res (2009) 1.09
Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol (2013) 1.07
Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach. J Cancer (2015) 1.07
Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol (2002) 1.05
Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun (2014) 1.04
Cancer genetics: tumor suppressor meets oncogene. Curr Biol (1999) 1.02
Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med (Berl) (2011) 1.02
CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci U S A (2012) 0.99
Molecular genetics of colorectal cancer. Ann N Y Acad Sci (1995) 0.96
Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci (2014) 0.95
BRD4 inhibitor inhibits colorectal cancer growth and metastasis. Int J Mol Sci (2015) 0.86
Pooled RNAi Screens - Technical and Biological Aspects. Curr Genomics (2010) 0.84
Hypermethylation of a cluster of Krüppel-type zinc finger protein genes on chromosome 19q13 in oropharyngeal squamous cell carcinoma. Am J Pathol (2011) 0.84
'Lnc'-ing enhancers to MYC regulation. Cell Res (2014) 0.82
Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. J Pathol (2015) 0.82
Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol (2014) 0.81
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell (2006) 20.92
Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (2009) 20.49
Ribo-gnome: the big world of small RNAs. Science (2005) 10.10
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal (2010) 8.61
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol (2002) 8.37
A protein sensor for siRNA asymmetry. Science (2004) 7.77
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell (2002) 6.43
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell (2008) 5.38
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
RISC assembly defects in the Drosophila RNAi mutant armitage. Cell (2004) 4.88
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell (2010) 3.60
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol (2002) 3.17
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res (2007) 2.86
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics (2009) 2.49
The serine/threonine/tyrosine phosphoproteome of the model bacterium Bacillus subtilis. Mol Cell Proteomics (2007) 2.40
Phosphoproteome analysis of E. coli reveals evolutionary conservation of bacterial Ser/Thr/Tyr phosphorylation. Mol Cell Proteomics (2007) 2.39
Developmental control of late replication and S phase length. Curr Biol (2010) 2.10
Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol Cell (2010) 2.10
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res (2010) 1.92
A distinct class of small RNAs arises from pre-miRNA-proximal regions in a simple chordate. Nat Struct Mol Biol (2009) 1.90
Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res (2012) 1.76
Systems-wide proteomic analysis in mammalian cells reveals conserved, functional protein turnover. J Proteome Res (2011) 1.75
A quartet of PIF bHLH factors provides a transcriptionally centered signaling hub that regulates seedling morphogenesis through differential expression-patterning of shared target genes in Arabidopsis. PLoS Genet (2013) 1.73
Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res (2008) 1.68
Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma. Mol Syst Biol (2012) 1.54
Mapping N-glycosylation sites across seven evolutionarily distant species reveals a divergent substrate proteome despite a common core machinery. Mol Cell (2012) 1.53
Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. Proc Natl Acad Sci U S A (2003) 1.53
Measuring the stoichiometry and physical interactions between components elucidates the architecture of the vertebrate kinetochore. Mol Biol Cell (2005) 1.52
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
Neural-specific elongation of 3' UTRs during Drosophila development. Proc Natl Acad Sci U S A (2011) 1.40
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res (2013) 1.38
Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS One (2010) 1.36
CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Res (2012) 1.35
Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics (2008) 1.27
Caenorhabditis elegans has a phosphoproteome atypical for metazoans that is enriched in developmental and sex determination proteins. J Proteome Res (2009) 1.26
Systems-wide analysis of a phosphatase knock-down by quantitative proteomics and phosphoproteomics. Mol Cell Proteomics (2009) 1.26
In situ validation of an intestinal stem cell signature in colorectal cancer. Gut (2012) 1.26
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res (2012) 1.23
Stable isotope labeling by amino acids in cell culture (SILAC) applied to quantitative proteomics of Bacillus subtilis. J Proteome Res (2010) 1.23
CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One (2010) 1.22
Genome-wide identification of chromosomal regions of increased tumor expression by transcriptome analysis. Cancer Res (2003) 1.21
Differential detection of five mouse-infecting helicobacter species by multiplex PCR. Clin Diagn Lab Immunol (2005) 1.20
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol (2009) 1.19
The Ser/Thr/Tyr phosphoproteome of Lactococcus lactis IL1403 reveals multiply phosphorylated proteins. Proteomics (2008) 1.18
Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J Am Chem Soc (2013) 1.14
Hand-carried cardiac ultrasound enhances healthcare delivery in developing countries. Am J Cardiol (2004) 1.13
Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc Natl Acad Sci U S A (2012) 1.12
Ser/Thr/Tyr protein phosphorylation in the archaeon Halobacterium salinarum--a representative of the third domain of life. PLoS One (2009) 1.10
A unique paradigm for a Turn-ON near-infrared cyanine-based probe: noninvasive intravital optical imaging of hydrogen peroxide. J Am Chem Soc (2011) 1.10
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl (2009) 1.09
Pattern formation by a moving morphogen source. Phys Biol (2011) 1.07
C2 domain-containing phosphoprotein CDP138 regulates GLUT4 insertion into the plasma membrane. Cell Metab (2011) 1.03
Protein identification: the origins of peptide mass fingerprinting. J Am Soc Mass Spectrom (2003) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Phosphoproteins of the chicken eggshell calcified layer. Proteomics (2007) 1.02
Profiling the Trypanosoma cruzi phosphoproteome. PLoS One (2011) 1.01
Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol (2014) 0.99
Evolving enhancer-promoter interactions within the tinman complex of the flour beetle, Tribolium castaneum. Development (2009) 0.99
GEPIS--quantitative gene expression profiling in normal and cancer tissues. Bioinformatics (2004) 0.96
Real-time monitoring of drug release. Chem Commun (Camb) (2009) 0.95
MBASED: allele-specific expression detection in cancer tissues and cell lines. Genome Biol (2014) 0.93
Trl-GAGA directly interacts with lola like and both are part of the repressive complex of Polycomb group of genes. Mech Dev (2003) 0.92
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal (2013) 0.91
Prospective identification of glioblastoma cells generating dormant tumors. PLoS One (2012) 0.90
Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. BMC Genomics (2015) 0.88
Combination strategies for repair, plasticity, and regeneration using regulation of gene expression during the chronic phase after spinal cord injury. Synapse (2011) 0.88
Evolutionarily conserved paired immunoglobulin-like receptor α (PILRα) domain mediates its interaction with diverse sialylated ligands. J Biol Chem (2012) 0.88
A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models. J Neurosci (2014) 0.87
Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells (2012) 0.87
Recombinant Helicobacter bilis protein P167 for mouse serodiagnosis in a multiplex microbead assay. Clin Diagn Lab Immunol (2004) 0.86
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res (2014) 0.85
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm (2011) 0.83
Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg Med Chem (2009) 0.83
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol (2014) 0.82
An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res (2011) 0.81
Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization. J Am Chem Soc (2015) 0.81
Methods for assessing DNA hybridization of peptide nucleic acid-titanium dioxide nanoconjugates. Anal Biochem (2008) 0.81
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm (2015) 0.80
Integrative analysis of two cell lines derived from a non-small-lung cancer patient--a panomics approach. Pac Symp Biocomput (2014) 0.79
Suprachiasmatic nucleus neurons display endogenous resistance to excitotoxicity. Exp Biol Med (Maywood) (2010) 0.79
Phosphoproteome of Pristionchus pacificus provides insights into architecture of signaling networks in nematode models. Mol Cell Proteomics (2012) 0.79
Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier. Bioorg Med Chem (2007) 0.79
A digital atlas of ion channel expression patterns in the two-week-old rat brain. Neuroinformatics (2015) 0.79
Integrative genomic approaches to understanding cancer. Biochim Biophys Acta (2009) 0.78
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharmacol (2013) 0.78
The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. J Biol Chem (2012) 0.76
The effect of variable release kinetics on Paclitaxel efficacy from a drug eluting stent in a porcine model. EuroIntervention (2005) 0.76
Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy. Cancer Biol Ther (2012) 0.76